Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTHFD1 | P11586 | 2/20 | 0.44 |
| ▸ | DHFR | P00374 | 1/20 | 0.43 |
| ▸ | MTHFD2 | P13995 | 2/20 | 0.41 |
| ▸ | SOST | Q9BQB4 | 1/20 | 0.40 |
| ▸ | ATIC | P31939 | 4/20 | 0.39 |
| ▸ | GART | P22102 | 8/20 | 0.39 |
| ▸ | FOLR1 | P15328 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8406397 | 0.95 | FPGS (0.41) | MTHFD1DHFRMTHFD2SOSTATIC | |
| SCHEMBL5064786 | 0.90 | DHFR (0.46) | MTHFD1DHFRMTHFD2SOSTATIC | |
| SCHEMBL4616964 | 0.84 | MTHFD1 (0.47) | MTHFD1DHFRMTHFD2SOSTATIC | |
| Leucovorin SCHEMBL1259919 | 0.78 | DHFR (0.71) | MTHFD1DHFRMTHFD2SOSTATIC | |
| SCHEMBL17097094 | 0.78 | MTHFD1 (0.63) | MTHFD1DHFRMTHFD2SOSTATIC | |
| SCHEMBL2166341 | 0.78 | MTHFD1 (0.63) | MTHFD1DHFRMTHFD2SOSTATIC | |
| SCHEMBL2906514 | 0.77 | TYMS (0.62) | DHFRATICGART | |
| SCHEMBL14843581 | 0.74 | DHFR (0.46) | MTHFD1DHFRMTHFD2SOSTATIC | |
| SCHEMBL16085830 | 0.71 | MTHFD1 (0.55) | MTHFD1DHFRMTHFD2SOSTATIC | |
| SCHEMBL26045339 | 0.67 | TYMS (0.55) | MTHFD1DHFRMTHFD2SOSTATIC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019000101-A1 | NOVEL FORMULATIONS USEFUL IN TREATING FOLATE DEFICIENCIES | MSI METHYLATION SCIENCES INC. (CA) | 2019-01-03 | — | — | WO | disclosed |
| WO-2014143984-A1 | METHODS OF PRODUCING NUTRITIONAL SUPPLEMENTS USING MUSHROOMS FROM THE SPECIES PORIA COCOS OR FLAMMULINA VELUTIPES | JARROW FORMULAS, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20140271704-A1 | METHODS OF PRODUCING NUTRITIONAL SUPPLEMENTS USING MUSHROOMS FROM THE SPECIES Poria cocos OR Flammulina velutipes | JARROW FORMULAS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-8222022-B2 | Tri-functionalized cryptophane biosensors | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2012-07-17 | — | — | US | disclosed |
| US-20100105099-A1 | TRI-FUNCTIONALIZED CRYPTOPHANE, SYNTHESIS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-04-29 | — | — | US | disclosed |
| US-7682606-B2 | Methods of producing edible fungi containing activated folates and nutritional supplements containing activated folates | JARROW FORMULAS, INC. (US) | 2010-03-23 | — | — | US | disclosed |
| US-20080292596-A1 | METHODS OF PRODUCING EDIBLE FUNGI CONTAINING ACTIVATED FOLATES AND NUTRITIONAL SUPPLEMENTS CONTAINING ACTIVATED FOLATES | KKR LOAN ADMINISTRATION SERVICES LLC | 2008-11-27 | — | — | US | disclosed |
| US-7354590-B2 | Methods of producing edible fungi containing activated folates and nutritional supplements containing activated folates | JARROW FORMULAS, INC. (US) | 2008-04-08 | — | — | US | disclosed |
| WO-2004092334-A3 | METHODS OF PRODUCING EDIBLE FUNGI CONTAINING ACTIVATED FOLATES AND NUTRITIONAL SUPPLEMENTS CONTAINING ACTIVATED FOLATES | JARROW FORMULAS INC (US) | 2005-01-27 | — | — | WO | disclosed |
| US-20040258711-A1 | Methods of producing edible fungi containing activated folates and nutritional supplements containing activated folates | KKR LOAN ADMINISTRATION SERVICES LLC | 2004-12-23 | — | — | US | disclosed |
| WO-2004092334-A2 | METHODS OF PRODUCING EDIBLE FUNGI CONTAINING ACTIVATED FOLATES AND NUTRITIONAL SUPPLEMENTS CONTAINING ACTIVATED FOLATES | JARROW FORMULAS, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105099-A1 | TRI-FUNCTIONALIZED CRYPTOPHANE, SYNTHESIS AND USES THEREOF | SPR, CACYBP, CRY2 | MTHFD1 1413/4885DHFR 1874/4885MTHFD2 1084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.